We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gene Polymorphisms in Tacrolimus Drug Interactions (DDI-TAC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00620841
First Posted: February 22, 2008
Last Update Posted: February 22, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Fund for Scientific Research, Flanders, Belgium
Information provided by:
Katholieke Universiteit Leuven
February 13, 2008
February 22, 2008
February 22, 2008
May 2007
January 2008   (Final data collection date for primary outcome measure)
Tacrolimus exposure parameters [ Time Frame: weeks ]
Same as current
No Changes Posted
Tacrolimus daily dosing [ Time Frame: weeks ]
Same as current
Not Provided
Not Provided
 
Gene Polymorphisms in Tacrolimus Drug Interactions
Gene Polymorphisms in Tacrolimus Drug Interactions in Renal Transplant Patients
A retrospective analysis of the influence of gene polymorphisms on drug interactions between calcineurin-inhibitors and concomitant drugs in renal transplant patients.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Description:
DNA samples
Non-Probability Sample
Renal transplant recipients treated with a calcineurin-inhibitor
Renal Transplantation
Other: genotyping
Restriction fragment lenght polymorphisms
A
Patients treated with tacrolimus and experiencing a drug interaction
Intervention: Other: genotyping
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
January 2008
January 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Treatment with calcineurin-inhibitor
  • Renal transplantation

Exclusion Criteria:

  • Drug, alcohol addiction
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
 
NCT00620841
DDI-001
No
Not Provided
Not Provided
Catholic University Leuven, University Hospitals, University Hospital Gasthuisberg
Katholieke Universiteit Leuven
Fund for Scientific Research, Flanders, Belgium
Principal Investigator: Dirk R Kuypers, MD, PhD Universitaire Ziekenhuizen Leuven
Katholieke Universiteit Leuven
January 2008